▎WuXiEdited by Kant Content Team

Abcuro Announces $200 Million Series C Financing Led by New Enterprise Associates (NEA) with Participation from Foresite Capital; Existing Investors Include RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, Aberdeen Managed Funds, BlackRock Managed Funds and Accounts, Eurofarma Ventures, and Soleus Capital.

The proceeds from this Series C financing will be used to complete the registrational Phase 2/3 MUSCLE clinical trial, which aims to evaluate the efficacy and safety of Abcuro’s potential “first-in-class,” killer cell lectin-like receptor G1 (KLRG1)-targeted monoclonal antibody ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM).If the MUSCLE clinical trial results are positive, Abcuro plans to submit a Biologics License Application (BLA) and will allocate part of the funds to support preparations for commercial launch.

Ulviprubart is an investigational monoclonal antibody therapy targeting KLRG1, which can selectively deplete highly cytotoxic T cells while preserving naïve T cells, regulatory T cells, and central memory T cells. The drug is designed to treat diseases mediated by highly cytotoxic T cells, including inclusion body myositis and T-cell large granular lymphocytic leukemia (T-LGLL).Both the U.S. FDA and the European Medicines Agency (EMA) have granted ulviprubart orphan drug designation for the treatment of IBM.

▲Abcuro Pipeline Diagram (Source:Abcuro Official Website）

Inclusion Body Myositis is an autoimmune disease characterized by high cytotoxicity in patients.TCells continuously attack muscle tissue, leading to progressive weakness and atrophy of the limb muscles in patients.Patients gradually lose muscle function, manifested by grip strength, fine motor skills, and mobility.The decline.Currently, there are no approved treatments available that can alter the course of the disease.IBM。Based on published epidemiological literature, it is estimated that in the United States and EuropeIBMThe total number of patients exceeds510,000 people.

[1] Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis. Retrieved February 12, 2025 from https://www.businesswire.com/news/home/20250212455038/en/Abcuro-Announces-200-Million-Series-C-Financing-to-Advance-Its-First-In-Class-Medicine-in-Development-for-Inclusion-Body-Myositis

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规医院.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.